Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders

被引:33
作者
Oswald, Michaela [1 ]
Curran, Mark E. [2 ]
Lamberth, Sarah L. [2 ]
Townsend, Robert M. [3 ]
Hamilton, Jennifer D. [4 ]
Chernoff, David N. [5 ]
Carulli, John [6 ]
Townsend, Michael J. [7 ]
Weinblatt, Michael E. [8 ]
Kern, Marlena [1 ]
Pond, Cassandra M. [1 ]
Lee, Annette [1 ]
Gregersen, Peter K. [1 ]
机构
[1] Feinstein Inst Med Res, Manhasset, NY 11030 USA
[2] Janssen Res & Dev, Spring House, PA USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Regeneron Pharmaceut, Tarrytown, NY USA
[5] Chernoff Consulting LLC, Sausalito, CA USA
[6] Biogen Idec Inc, Cambridge, MA USA
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
DISEASE-ACTIVITY; INFLIXIMAB; THERAPY; CELLS; PREDICTS;
D O I
10.1002/art.38947
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To establish whether the analysis of whole-blood gene expression is useful in predicting or monitoring response to anti-tumor necrosis factor (anti-TNF) therapy in patients with rheumatoid arthritis (RA). Methods. Whole-blood RNA (using a PAXgene system to stabilize whole-blood RNA in the collection tube) was obtained at baseline and at 14 weeks from 3 independent cohorts, consisting of a combined total of 240 RA patients who were beginning therapy with anti-TNF. We used an approach to gene expression analysis that is based on modular patterns of gene expression, or modules. Results. Good and moderate responders according to the European League Against Rheumatism criteria exhibited highly significant and consistent changes in multiple gene expression modules after 14 weeks of therapy, as demonstrated by hypergeometric analysis. Strikingly, nonresponders exhibited very little change in any modules, despite exposure to TNF blockade. These patterns of change were highly consistent across all 3 cohorts, indicating that immunologic changes after TNF treatment are specific to the combination of both drug exposure and responder status. In contrast, modular patterns of gene expression did not exhibit consistent differences between responders and nonresponders at baseline in the 3 study cohorts. Conclusion. These data provide evidence that using gene expression modules related to inflammatory disease may provide a valuable method for objective monitoring of the response of RA patients who are treated with TNF inhibitors.
引用
收藏
页码:344 / 351
页数:8
相关论文
共 23 条
  • [1] Convergent random forest predictor: Methodology for predicting drug response from genome-scale data applied to anti-TNF response
    Bienkowska, Jadwiga R.
    Dalgin, Gul S.
    Batliwalla, Franak
    Allaire, Normand
    Roubenoff, Ronenn
    Gregersen, Peter K.
    Carulli, John P.
    [J]. GENOMICS, 2009, 94 (06) : 423 - 432
  • [2] Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis
    Centola, Michael
    Cavet, Guy
    Shen, Yijing
    Ramanujan, Saroja
    Knowlton, Nicholas
    Swan, Kathryn A.
    Turner, Mary
    Sutton, Chris
    Smith, Dustin R.
    Haney, Douglas J.
    Chernoff, David
    Hesterberg, Lyndal K.
    Carulli, John P.
    Taylor, Peter C.
    Shadick, Nancy A.
    Weinblatt, Michael E.
    Curtis, Jeffrey R.
    [J]. PLOS ONE, 2013, 8 (04):
  • [3] A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus
    Chaussabel, Damien
    Quinn, Charles
    Shen, Jing
    Patel, Pinakeen
    Glaser, Casey
    Baldwin, Nicole
    Stichweh, Dorothee
    Blankenship, Derek
    Li, Lei
    Munagala, Indira
    Bennett, Lynda
    Allantaz, Florence
    Mejias, Asuncion
    Ardura, Monica
    Kaizer, Ellen
    Monnet, Laurence
    Allman, Windy
    Randall, Henry
    Johnson, Diane
    Lanier, Aimee
    Punaro, Marilynn
    Wittkowski, Knut M.
    White, Perrin
    Fay, Joseph
    Klintmalm, Goran
    Ramilo, Octavio
    Palucka, A. Karolina
    Banchereau, Jacques
    Pascual, Virginia
    [J]. IMMUNITY, 2008, 29 (01) : 150 - 164
  • [4] Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
    Curtis, Jeffrey R.
    van der Helm-van Mil, Annette H.
    Knevel, Rachel
    Huizinga, Tom W.
    Haney, Douglas J.
    Shen, Yijing
    Ramanujan, Saroja
    Cavet, Guy
    Centola, Michael
    Hesterberg, Lyndal K.
    Chernoff, David
    Ford, Kerri
    Shadick, Nancy A.
    Hamburger, Max
    Fleischmann, Roy
    Keystone, Edward
    Weinblatt, Michael E.
    [J]. ARTHRITIS CARE & RESEARCH, 2012, 64 (12) : 1794 - 1803
  • [5] lumi:: a pipeline for processing Illumina microarray
    Du, Pan
    Kibbe, Warren A.
    Lin, Simon M.
    [J]. BIOINFORMATICS, 2008, 24 (13) : 1547 - 1548
  • [6] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned?
    Feldmann, M
    Maini, RN
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 163 - 196
  • [7] The Power of a Modular Approach to Transcriptional Analysis
    Gregersen, Peter K.
    Oswald, Michaela
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (06) : 1418 - 1420
  • [8] An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis
    Julia, Antonio
    Erra, Alba
    Palacio, Carles
    Tomas, Carlos
    Sans, Xavier
    Barcelo, Pere
    Marsal, Sara
    [J]. PLOS ONE, 2009, 4 (10):
  • [9] Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year
    Kay, Jonathan
    Morgacheva, Olga
    Messing, Susan P.
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    Reed, George W.
    Gravallese, Ellen M.
    Furst, Daniel E.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
  • [10] Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
    Koczan, Dirk
    Drynda, Susanne
    Hecker, Michael
    Drynda, Andreas
    Guthke, Reinhard
    Kekow, Joern
    Thiesen, Hans-Juergen
    [J]. ARTHRITIS RESEARCH & THERAPY, 2008, 10 (03)